Comp
As the FDA sees another quarter with a net loss of employees in CDER and CBER, Pink Sheet editors discuss the potential impact and where it could manifest.
After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines.
Medtech Insight was invited to moderate a panel discussion with leading experts in neuroscience and AI during INBRAIN’s five-year anniversary in Barcelona, Spain. Panelists discussed the promises, perils in BCI development, neuroethics and outlook.
HBW Insight speaks to ex-Perrigo ESG expert Steve Ramus about the state of sustainability in consumer health and where we might be heading in the near future. Part one of two.
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Pink Sheet editors discuss new information on the Commissioner’s National Priority Voucher Program, including the role of the center directors and the Commissioner’s National Priority Voucher Review Council in application reviews.
Industry associations in the UK, Germany and Greece expect 2026 to be the year self‑care policy is translated into day‑to‑day system change. They highlight opportunities in pharmacy, digital tools and regulatory reform, but warn that progress depends on political timing and regulatory agility.
A new report by Bayer, GSCF and BCIU predicts that 2026 may be pivotal for embedding self‑care into global health policy, as progress toward universal healthcare has stalled and urgent, evidence‑driven advocacy is needed to ensure self‑care becomes a core, scalable component of health systems.
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.